Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Profile of Nagasaki Islands Study (NaIS): A Population-based Prospective Cohort Study on Multi-disease.
Miyata J, Yamanashi H, Kawashiri SY, Soutome S, Arima K, Tamai M, Nonaka F, Honda Y, Kitamura M, Yoshida K, Shimizu Y, Hayashida N, Kawakami S, Takamura N, Sawase T, Yoshimura A, Nagata Y, Ohnishi M, Aoyagi K, Kawakami A, Saito T, Maeda T. Miyata J, et al. Among authors: tamai m. J Epidemiol. 2024 May 5;34(5):254-263. doi: 10.2188/jea.JE20230079. Epub 2023 Dec 28. J Epidemiol. 2024. PMID: 37517991 Free PMC article.
Association between Epstein-Barr virus serological reactivation and psychological distress: a cross-sectional study of Japanese community-dwelling older adults.
Yamanashi H, Akabame S, Miyata J, Honda Y, Nonaka F, Shimizu Y, Nakamichi S, Kawashiri SY, Tamai M, Arima K, Kawakami A, Aoyagi K, Maeda T. Yamanashi H, et al. Among authors: tamai m. Aging (Albany NY). 2022 Oct 21;14(20):8258-8269. doi: 10.18632/aging.204345. Epub 2022 Oct 21. Aging (Albany NY). 2022. PMID: 36279393 Free PMC article.
Immunoglobulin G4-related Disease with Marked Eosinophilia: A Case Report and Literature Review.
Origuchi T, Uchida T, Sakaguchi T, Matsuo H, Michitsuji T, Umeda M, Shimizu T, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Ichinose M, Ando K, Horie I, Nakao N, Irie J, Kawakami A. Origuchi T, et al. Among authors: tamai m. Intern Med. 2023 Jun 15;62(12):1849-1855. doi: 10.2169/internalmedicine.0453-22. Epub 2022 Nov 9. Intern Med. 2023. PMID: 36351576 Free PMC article. Review.
Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N, Chiba K, Sato S, Shiraishi K, Watanabe K, Oki N, Okada A, Koga T, Kawashiri SY, Tamai M, Hosogaya N, Furuyama M, Kobayashi M, Saito K, Okubo N, Uetani M, Osaki M, Kawakami A. Iwamoto N, et al. Among authors: tamai m. Arthritis Res Ther. 2022 Dec 7;24(1):264. doi: 10.1186/s13075-022-02957-w. Arthritis Res Ther. 2022. PMID: 36476479 Free PMC article. Clinical Trial.
Identification of risk factors for elevated serum IgG4 levels in subjects in a large-scale health checkup cohort study.
Tsuji Y, Koga T, Nonaka F, Nobusue K, Kawashiri SY, Yamanashi H, Maeda T, Arima K, Aoyagi K, Takahashi M, Kawaguchi S, Matsuda F, Fujii H, Kawano M, Nakamura H, Kawakami A, Tamai M. Tsuji Y, et al. Among authors: tamai m. Front Immunol. 2023 Mar 8;14:1124417. doi: 10.3389/fimmu.2023.1124417. eCollection 2023. Front Immunol. 2023. PMID: 36969256 Free PMC article.
Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry-a historical cohort study.
Ichinose K, Sato S, Igawa T, Okamoto M, Takatani A, Endo Y, Tsuji S, Shimizu T, Sumiyoshi R, Koga T, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Yajima N, Sada KE, Miyawaki Y, Yoshimi R, Shimojima Y, Ohno S, Kajiyama H, Sato S, Fujiwara M, Kawakami A. Ichinose K, et al. Among authors: tamai m. Arthritis Res Ther. 2024 Feb 12;26(1):48. doi: 10.1186/s13075-024-03285-x. Arthritis Res Ther. 2024. PMID: 38347556 Free PMC article.
Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab.
Umeda M, Kojima K, Michitsuji T, Tsuji Y, Shimizu T, Fukui S, Sumiyoshi R, Koga T, Kawashiri SY, Naoki I, Iagawa T, Tamai M, Origuchi T, Furuyama M, Tsuboi M, Matsuoka N, Okada A, Aramaki T, Kawakami A. Umeda M, et al. Among authors: tamai m. Mod Rheumatol. 2024 May 4:roae038. doi: 10.1093/mr/roae038. Online ahead of print. Mod Rheumatol. 2024. PMID: 38756072 No abstract available.
900 results